Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
DOI:
https://doi.org/10.2340/00015555-3848Abstract
Abstract is missing (Short communication)
Downloads
References
Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71: 327–349.
Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol 2018; 178: 768–775.
Senner S, Seegräber M, Frey S, Kendziora B, Eicher L, Wollenberg A. Dupilumab for the treatment of adolescents with atopic dermatitis. Expert Rev Clin Immunol 2020; 16: 641–650.
Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol 2017; 77: 623–633.
Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014; 111: 5147–5152.
Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014; 111: 5153–5158.
US Food and Drug Administration. Dupixent® (dupilumab). Highlights of prescribing information. 2020 (accessed March 2021). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761055s015s017lbl.pdf.
Health Canada. DUPIXENT® Canada Product Monograph. February 22, 2021 (accessed March 2021). Available from: https://pdf.hres.ca/dpd_pm/00060069.PDF
European Medicines Agency. Dupixent® (dupilumab). Summary of product characteristics. 2019 (accessed March 2021). Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf.
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 44–56.
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70: 338–351.
Published
How to Cite
License
Copyright (c) 2021 Mette Deleuran, Danielle Marcoux, Marjolein S. De Bruin-Weller, Alan D. Irvine, Eulalia Baselga, Kangmo Ahn, Ana Paula Castro, Ashish Bansal, Jingdong Chao, Gaëlle Bégo-Le-Bagousse, Ana B. Rossi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
